SummaryMultiple sclerosis (MS) ameliorates typically during pregnancy but after the delivery the relapse rate often increases. Our study was conducted to understand the immunoregulatory mechanisms accompanying this phenomenon. MS patients were followed-up prospectively during pregnancy and 6 months postpartum, with immunological characterization of the peripheral blood. Groups of age-and parity-matched healthy pregnant women, and age-and sex-matched non-pregnant women and non-pregnant MS patients were studied as controls. In our patient cohort, the annualized relapse rate was 1·0 Ϯ 1·0 relapses/woman/year (mean Ϯ standard deviation) during the year before pregnancy, but dropped to 0·2 Ϯ 0·9 during the third trimester (P = 0·02). After the delivery the relapse rate increased again to 1·4 Ϯ 1·9 (1-3 months postpartum versus third trimester P = 0·003). While percentages of peripheral blood CD3, CD4, CD8 and CD19 immune cell subsets were unchanged over the observation period, reduced disease activity during the last trimester was associated with a significant increase in the percentage of circulating CD56 bright natural killer (NK) cells. Simultaneously, the proportion of circulating CD56 dim NK cells was clearly reduced. No alteration was noted in CD4 + CD25 high forkhead box P3 + regulatory T cells. Production of interferon-gamma by peripheral blood lymphocytes was down-regulated significantly during pregnancy in comparison to the postpartum period, resulting in an increased T helper type 2 (Th2) : Th1 ratio during pregnancy. In conclusion, pregnant state in MS patients is characterized by an increase in the percentage of CD56 bright NK cells and by enhanced Th2 type cytokine secretion. Our findings suggest a potential role for CD56 bright regulatory NK cells in the control of autoimmune inflammation during pregnancy in MS.

No abstract

Intravenous immunoglobulin did not show inferiority compared with IVMP in the treatment of an acute MS relapse evaluated clinically and radiologically. Therefore, we suggest that IVIG may be tried as a therapy in acute MS relapse, especially in case of contraindications to IVMP and plasmapheresis.

No abstract